APTO vs. ELEV, DTIL, SRZN, PASG, OKYO, INKT, JATT, CRIS, CLDI, and CVM
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Elevation Oncology (ELEV), Precision BioSciences (DTIL), Surrozen (SRZN), Passage Bio (PASG), OKYO Pharma (OKYO), MiNK Therapeutics (INKT), JATT Acquisition (JATT), Curis (CRIS), Calidi Biotherapeutics (CLDI), and CEL-SCI (CVM). These companies are all part of the "biological products, except diagnostic" industry.
Aptose Biosciences vs.
Elevation Oncology (NASDAQ:ELEV) and Aptose Biosciences (NASDAQ:APTO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.
83.7% of Elevation Oncology shares are held by institutional investors. Comparatively, 26.6% of Aptose Biosciences shares are held by institutional investors. 8.1% of Elevation Oncology shares are held by company insiders. Comparatively, 1.3% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Elevation Oncology had 6 more articles in the media than Aptose Biosciences. MarketBeat recorded 6 mentions for Elevation Oncology and 0 mentions for Aptose Biosciences. Elevation Oncology's average media sentiment score of 1.19 beat Aptose Biosciences' score of 0.00 indicating that Elevation Oncology is being referred to more favorably in the media.
Elevation Oncology has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 0.88, meaning that its share price is 12% less volatile than the S&P 500.
Aptose Biosciences received 346 more outperform votes than Elevation Oncology when rated by MarketBeat users. However, 76.09% of users gave Elevation Oncology an outperform vote while only 62.46% of users gave Aptose Biosciences an outperform vote.
Elevation Oncology's return on equity of -59.73% beat Aptose Biosciences' return on equity.
Elevation Oncology is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Elevation Oncology presently has a consensus target price of $7.20, indicating a potential upside of 1,098.00%. Aptose Biosciences has a consensus target price of $4.33, indicating a potential upside of 2,320.86%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Elevation Oncology.
Summary
Elevation Oncology beats Aptose Biosciences on 11 of the 14 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APTO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aptose Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:APTO) was last updated on 2/11/2025 by MarketBeat.com Staff